The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2024 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | 0.00% | +12.90% | +12.90% |
04-23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
04-16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2024 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+12.90% | 293M | |
+2.93% | 108B | |
-2.79% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |